Is Screening With Magnetic Resonance Imaging in BRCA Mutation Carriers a Safe and Effective Alternative to Prophylactic Mastectomy?

2011 ◽  
Vol 29 (13) ◽  
pp. 1652-1654 ◽  
Author(s):  
Monika L. Burness ◽  
Olufunmilayo I. Olopade
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Prophylactic Mastectomy ◽  
Brca Mutation ◽  
Effective Alternative ◽  
Resonance Imaging ◽  
Mutation Carriers ◽  
Brca Mutation Carriers

Acquired megaesophagus in a dog – case report

2021 ◽  
Vol XXVI (150) ◽  
pp. 46-55
Author(s):  
Bruna Dias Fagundes ◽  
Mariana C. H. Rondelli ◽  
Eduarda A. N. L. D. Cavalcanti ◽  
Arthur de Lima Espinosa ◽  
Carina Burkert da Silva ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Case Report ◽  
Magnetic Resonance ◽  
Barium Sulphate ◽  
Effective Alternative ◽  
Resonance Imaging ◽  
Esophageal Dilatation ◽  
Pet Food ◽  
Alternative Method ◽  
History Of

Acquired megaesophagus is an uncommon cause of regurgitation in dogs. Diagnosis is confirmed by simple or contrast radiographs, endoscopy, tomography, scintigraphy, or magnetic resonance imaging. Esophagography with barium sulphate contrast is the most commonly used method, however, it may be inconclusive if dilation marking does not occur. This paper reports the case of a 9-year-old female dog, with a history of regurgitation over six months, simple and contrast radiographic exams showing no evidence of megaesophagus. The esophagography exam was repeated with the addition of barium contrast mixed with commercial dry pet food, which verified esophageal dilatation and confirmed megaesophagus. Although this technique is not widely used, it is an effective alternative method for diagnosis of canine megaesophagus, particularly when other radiographic approaches are inconclusive.

scholarly journals Occipital Cortical Calcifications in Cerebral Amyloid Angiopathy

Stroke ◽  
2021 ◽  
Vol 52 (5) ◽  
pp. 1851-1855
Author(s):  
Ingeborg Rasing ◽  
Sabine Voigt ◽  
Emma A. Koemans ◽  
Erik van Zwet ◽  
Paul C. de Kruijff ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Computed Tomography ◽  
Magnetic Resonance ◽  
Cerebral Amyloid Angiopathy ◽  
Occipital Cortex ◽  
Amyloid Angiopathy ◽  
Resonance Imaging ◽  
Striped Pattern ◽  
Mutation Carriers ◽  
Cerebral Amyloid

Background and Purpose: Cortical calcifications have been reported in patients with cerebral amyloid angiopathy (CAA), although their prevalence and pathophysiology are unknown. We investigated the frequency of calcifications on computed tomography, their association with intracerebral hemorrhage (ICH) and their coexistence with a striped pattern of the occipital cortex reflecting microcalcifications on ultra-high-field 7T-magnetic resonance imaging in Dutch-type hereditary CAA (D-CAA) and sporadic CAA. Methods: We included D-CAA mutation carriers with a proven APP (amyloid precursor protein) mutation or ≥1 lobar ICH and ≥1 first-degree relative with D-CAA and sporadic CAA patients with probable CAA according to the modified Boston criteria. D-CAA carriers were regarded symptomatic when they had a history of symptomatic ICH. We assessed the presence, location, and progression of calcifications and their association with ICH and the striped occipital cortex. Results: We found cortical calcifications in 15/81 (19% [95% CI, 11–29]) D-CAA mutation carriers (15/69 symptomatic and 0/12 presymptomatic) and in 1/59 (2% [95% CI, 0–9]) sporadic CAA patients. Calcifications were all bilateral located in the occipital lobes. In 3/15 (20%) of the symptomatic D-CAA patients the calcifications progressed over a period up to 10 years. There was evidence of an association between cortical calcifications and new ICH development (hazard ratio, 7.1 [95% CI, 0.9–54.9], log-rank P =0.03). In 7/25 D-CAA symptomatic carriers in whom a 7T-magnetic resonance imaging was performed, a striped pattern of the occipital cortex was present; in 3/3 (100%) of those with calcifications on computed tomography and 4/22 (18%) of those without calcifications. Conclusions: Occipital cortical calcifications are frequent in D-CAA but seem to be rare in sporadic CAA. Their absence in presymptomatic carriers and their association with ICH might suggest that they are a marker for advanced CAA. Cortical calcifications on computed tomography seem to be associated with the striped occipital cortex on 7T-magnetic resonance imaging which may possibly represent an early stage of calcification.

scholarly journals Four magnetic resonance imaging surveillance-detected breast cancer cases in cancer-free BRCA1/2 mutation carriers

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Megumi Takaoka ◽  
Shozo Ohsumi ◽  
Yuichiro Miyoshi ◽  
Mina Takahashi ◽  
Seiki Takashima ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Magnetic Resonance Imaging ◽  
Ovarian Cancer ◽  
Magnetic Resonance ◽  
Breast Mri ◽  
Resonance Imaging ◽  
Breast And Ovarian Cancer ◽  
Guided Biopsy ◽  
Mutation Carriers ◽  
Mri Surveillance

Abstract Background Hereditary breast and ovarian cancer (HBOC) syndrome is a susceptibility syndrome for cancers, such as breast and ovarian cancer, and BRCA1/2 are its causative genes. Annual breast-enhanced magnetic resonance imaging (MRI) is recommended for BRCA1/2 mutation carriers aged over 25 years as a secondary prevention of breast cancer. However, breast MRI surveillance is rarely performed in Japan, and only four cases of breast cancer diagnosis triggered by MRI surveillance have been reported. Case presentation At our hospital, MRI triggered the diagnosis of breast cancer in four cancer-free BRCA1/2 mutation carriers. In one of our four cases, although MRI showed only a 3-mm focus, we could diagnose breast cancer by shortening the surveillance interval considering the patient’s high-risk for developing breast cancer. Conclusions Image-guided biopsy, including MRI-guided biopsy, depending on the size of the lesion, and shorter surveillance intervals are useful when there are potentially malignant findings on breast MRI surveillance for cancer-free patients with HBOC.

scholarly journals Aromatase Inhibitors and Contralateral Breast Cancer in BRCA Mutation Carriers: A long-term Follow-up

2021 ◽  
Author(s):  
Maryam Nemati Shafaee ◽  
Kristina Goutsouliak ◽  
Heather Lin ◽  
Therese B Bevers ◽  
Angelica Gutierrez-Barrera ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Aromatase Inhibitors ◽  
Prophylactic Mastectomy ◽  
Brca Mutation ◽  
Brca1 Mutation ◽  
Brca2 Mutation ◽  
Mutation Status ◽  
Mutation Carriers ◽  
Brca Mutation Carriers

Abstract Background: Deleterious BRCA mutations confer a significant lifetime risk of breast cancer (BC) as well as contralateral BC (CBC) in patients who do not undergo prophylactic mastectomy. Prior reports have suggested that tamoxifen reduces the risk of CBC in BRCA mutation carriers. Whether aromatase inhibitors (AI) have the same effect is unknown. Methods: This is a retrospective review of patients diagnosed with non-metastatic ER+ BC between 2004-2014 with known BRCA mutation status. Patients were followed from primary diagnosis until CBC diagnosis or death. Median follow up was 11.5 years. Risk of CBC was evaluated as time to event. Results: 935 subjects were included in this analysis, with 53 BRCA1 mutation carriers, and 94 BRCA2 mutation carriers. Median age at diagnosis was 42.7 years. Seventy-two percent (676) received tamoxifen and 43% (405) received AI. A total of 66 CBCs occurred, of which 10% (15/147) occurred in BRCA mutation carriers vs %6.5 (51/788) in BRCA wild type. Multivariate analyses indicated that BRCA status and AI use were significantly associated with CBC risk. AI use resulted in a significant reduction in risk of CBC (HR 0.44, p=0.004) regardless of the BRCA mutation status. Tamoxifen use was not associated with reduced risk of CBC. Conclusions: This is the first report showing that AIs reduce the risk of CBC in BRCA mutation carriers. The potential role of AIs as chemoprevention should be validated in larger independent cohorts.

Sign in / Sign up

Export Citation Format

Share Document